INHIBITION OF HUMAN CYTOCHROME P450 2D6 (CYP2D6) BY METHADONE

被引:92
作者
WU, D
OTTON, SV
SPROULE, BA
BUSTO, U
INABA, T
KALOW, W
SELLERS, EM
机构
[1] ADDICT RES FDN, INST CLIN RES & TREATMENT, 33 RUSSELL ST, TORONTO M5S 2S1, ONTARIO, CANADA
[2] UNIV TORONTO, DEPT MED, TORONTO M5S 1A1, ONTARIO, CANADA
[3] UNIV TORONTO, DEPT PHARMACOL, TORONTO M5S 1A1, ONTARIO, CANADA
[4] UNIV TORONTO, DEPT PSYCHIAT, TORONTO M5S 1A1, ONTARIO, CANADA
关键词
METHADONE; CYP2D6; DEXTROMETHORPHAN OXIDATION; PHENOTYPE; HUMAN LIVER MICROSOMES;
D O I
10.1111/j.1365-2125.1993.tb05666.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 In microsomes prepared from three human livers, methadone competitively inhibited the O-demethylation of dextromethorphan, a marker substrate for CYP2D6. The apparent K(i) value of methadone ranged from 2.5 to 5 mum. 2 Two hundred and fifty-two (252) white Caucasians, including 210 unrelated healthy volunteers and 42 opiate abusers undergoing treatment with methadone were phenotyped using dextromethorphan as the marker drug. Although the frequency of poor metabolizers was similar in both groups, the extensive metabolizers among the opiate abusers tended to have higher O-demethylation metabolic ratios and to excrete less of the dose as dextromethorphan metabolites than control extensive metabolizer subjects. These data suggest inhibition of CYP2D6 by methadone in vivo as well. 3 Because methadone is widely used in the treatment of opiate abuse, inhibition of CYP2D6 activity in these patients might contribute to exaggerated response or unexpected toxicity from drugs that are substrates of this enzyme.
引用
收藏
页码:30 / 34
页数:5
相关论文
共 45 条
[1]   BIOTRANSFORMATION OF METHADONE IN MAN - SYNTHESIS AND IDENTIFICATION OF A MAJOR METABOLITE [J].
BECKETT, AH ;
TAYLOR, JF ;
CASY, AF ;
HASSAN, MMA .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1968, 20 (10) :754-&
[2]  
BELL J, 1990, BRIT J ADDICT, V85, P1599
[3]  
BOOBIS AR, 1983, MOL PHARMACOL, V23, P474
[4]   SINGLE-DOSE QUINIDINE TREATMENT INHIBITS MEXILETINE OXIDATION IN EXTENSIVE METABOLIZERS OF DEBRISOQUINE [J].
BROLY, F ;
VANDAMME, N ;
CARON, J ;
LIBERSA, C ;
LHERMITTE, M .
LIFE SCIENCES, 1991, 48 (26) :PL123-PL128
[5]   CLINICAL-SIGNIFICANCE OF THE SPARTEINE-DEBRISOQUINE OXIDATION POLYMORPHISM [J].
BROSEN, K ;
GRAM, LF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) :537-547
[6]  
CAMPBELL ME, 1987, DRUG METAB DISPOS, V15, P237
[7]   SIMULTANEOUS DETERMINATION OF DEXTROMETHORPHAN AND 3 METABOLITES IN PLASMA AND URINE USING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH APPLICATION TO THEIR DISPOSITION IN MAN [J].
CHEN, ZR ;
SOMOGYI, AA ;
BOCHNER, F .
THERAPEUTIC DRUG MONITORING, 1990, 12 (01) :97-104
[8]   DEXTROMETHORPHAN O-DEMETHYLATION IN LIVER-MICROSOMES AS A PROTOTYPE REACTION TO MONITOR CYTOCHROME-P-450 DB1 ACTIVITY [J].
DAYER, P ;
LEEMANN, T ;
STRIBERNI, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (01) :34-40
[9]   BIOACTIVATION OF THE NARCOTIC DRUG CODEINE IN HUMAN-LIVER IS MEDIATED BY THE POLYMORPHIC MONOOXYGENASE CATALYZING DEBRISOQUINE 4-HYDROXYLATION (CYTOCHROME-P-450 DBL/BUFI) [J].
DAYER, P ;
DESMEULES, J ;
LEEMANN, T ;
STRIBERNI, R .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 152 (01) :411-416
[10]   IMPACT OF ENVIRONMENTAL AND GENETIC-FACTORS ON CODEINE ANALGESIA [J].
DESMEULES, J ;
GASCON, MP ;
DAYER, P ;
MAGISTRIS, M .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 41 (01) :23-26